ArticleJournal of clinical medicine2020
SERS-Based Liquid Biopsy of Gastrointestinal Tumors Using a Portable Raman Device Operating in a Clinical Environment.
Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 34 citations in OpenAlex.
- Rapid serum-based differentiation of ovarian tumors and assessment of post-treatment disease-free status using portable Raman spectroscopy and machine learning.Analytical and bioanalytical chemistry · 2026Article
- Research progress of surface-enhanced Raman scattering technology in tumor liquid biopsy.Frontiers in molecular biosciences · 2026Review
- SERS-guided photodynamic therapy: pioneering strategies in advanced cancer diagnosis and treatment.Discover nano · 2025Review
- Application of Raman Spectroscopy in Non-Invasive Analysis of the Gut Microbiota and Its Impact on Gastrointestinal Health.Diagnostics (Basel, Switzerland) · 2025Review
- Spectroscopic characterization of bacterial colonies through UV hyperspectral imaging techniques.Frontiers in chemistry · 2025Article
- Scientific Advances in Cancer Detection Using Raman Spectroscopy.Asian Pacific journal of cancer prevention : APJCP · 2024Review
- A Review on Integrated ZnO-Based SERS Biosensors and Their Potential in Detecting Biomarkers of Neurodegenerative Diseases.Biosensors · 2023Review
- Recent Trends in SERS-Based Plasmonic Sensors for Disease Diagnostics, Biomolecules Detection, and Machine Learning Techniques.Biosensors · 2023Review
- SERS Liquid Biopsy Profiling of Serum for the Diagnosis of Kidney Cancer.Biomedicines · 2022Article
- Acoustofluidic multimodal diagnostic system for Alzheimer's disease.Biosensors & bioelectronics · 2022Article
- Raman Spectroscopy: A Novel Technology for Gastric Cancer Diagnosis.Frontiers in bioengineering and biotechnology · 2022Review
- Recent advances in surface-enhanced Raman spectroscopy based liquid biopsy for colorectal cancer (Review).Experimental and therapeutic medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
Abstract
Early diagnosis based on screening is recognized as one of the most efficient ways of mitigating cancer-associated morbidity and mortality. Therefore, reliable but cost-effective methodologies are needed. By using a portable Raman spectrometer, a small and easily transportable instrument, the needs of modern diagnosis in terms of rapidity, ease of use and flexibility are met. In this study, we analyzed the diagnostic accuracy yielded by the surface-enhanced Raman scattering (SERS)-based profiling of serum, performed with a portable Raman device operating in a real-life hospital environment, in the case of 53 patients with gastrointestinal tumors and 25 control subjects. The SERS spectra of serum displayed intense bands attributed to carotenoids and purine metabolites such as uric acid, xanthine and hypoxanthine, with different intensities between the cancer and control groups. Based on principal component analysis-quadratic discriminant analysis (PCA-QDA), the cancer and control groups were classified with an accuracy of 76.92%. By combining SERS spectra with general inflammatory markers such as C-reactive protein levels, neutrophil counts, platelet counts and hemoglobin levels, the discrimination accuracy was increased to 83.33%. This study highlights the potential of SERS-based liquid biopsy for the point-of-care diagnosis of gastrointestinal tumors using a portable Raman device operating in a clinical setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.